Alzheimer's Disease - Pipeline Review, H1 2018

  • ID: 4464952
  • Drug Pipelines
  • 1203 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AB Science SA
  • AbbVie Inc
  • AC Immune SA
  • Accera Inc
  • Actinogen Medical Ltd
  • Addex Therapeutics Ltd
  • MORE
Alzheimer's Disease - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Alzheimer's Disease - Pipeline Review, H1 2018, provides an overview of the Alzheimer's Disease (Central Nervous System) pipeline landscape.

Alzheimer's disease is a progressive, degenerative condition causing damage to the memory and behavior due to the attack on the neurons. These neurons are responsible for the synthesis of neurotransmitter acetylcholine which is further responsible for the transmission of signals. Predisposing factors include age, heredity, cardiovascular diseases or diabetes and environmental factors. Symptoms include depression, anxiety, social withdrawal, irritability and aggressiveness.

Report Highlights

The Publisher's Pharmaceutical and Healthcare latest pipeline guide Alzheimer's Disease - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Alzheimer's Disease (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alzheimer's Disease (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alzheimer's Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 23, 50, 56, 1, 253, 99 and 9 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 104 and 43 molecules, respectively.

Alzheimer's Disease (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourcedfrom the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alzheimer's Disease (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alzheimer's Disease (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alzheimer's Disease (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alzheimer's Disease (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alzheimer's Disease (Central Nervous System)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alzheimer's Disease (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alzheimer's Disease (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AB Science SA
  • AbbVie Inc
  • AC Immune SA
  • Accera Inc
  • Actinogen Medical Ltd
  • Addex Therapeutics Ltd
  • MORE
Introduction

Alzheimer's Disease - Overview

Alzheimer's Disease - Therapeutics Development

Alzheimer's Disease - Therapeutics Assessment

Alzheimer's Disease - Companies Involved in Therapeutics Development

Alzheimer's Disease - Drug Profiles

Alzheimer's Disease - Dormant Projects

Alzheimer's Disease - Discontinued Products

Alzheimer's Disease - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Alzheimer's Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Alzheimer's Disease - Pipeline by AB Science SA, H1 2018

Alzheimer's Disease - Pipeline by AbbVie Inc, H1 2018

Alzheimer's Disease - Pipeline by AC Immune SA, H1 2018

Alzheimer's Disease - Pipeline by Acadia Pharmaceuticals Inc, H1 2018

Alzheimer's Disease - Pipeline by Accera Inc, H1 2018

Alzheimer's Disease - Pipeline by Actinogen Medical Ltd, H1 2018

Alzheimer's Disease - Pipeline by Acumen Pharmaceuticals Inc, H1 2018

Alzheimer's Disease - Pipeline by Addex Therapeutics Ltd, H1 2018

Alzheimer's Disease - Pipeline by Aequus Pharmaceuticals Inc, H1 2018

Alzheimer's Disease - Pipeline by AFFiRiS AG, H1 2018

Alzheimer's Disease - Pipeline by Alector LLC, H1 2018

Alzheimer's Disease - Pipeline by Allergan Plc, H1 2018

Alzheimer's Disease - Pipeline by Allgenesis Biotherapeutics Inc, H1 2018

Alzheimer's Disease - Pipeline by Allinky Biopharma, H1 2018

Alzheimer's Disease - Pipeline by ALSP Inc, H1 2018

Alzheimer's Disease - Pipeline by Alzhyme Pty Ltd, H1 2018

Alzheimer's Disease - Pipeline by Alzinova AB, H1 2018

Alzheimer's Disease - Pipeline by AlzProtect SAS, H1 2018

Alzheimer's Disease - Pipeline by Amarantus Bioscience Holdings Inc, H1 2018

Alzheimer's Disease - Pipeline by Amgen Inc, H1 2018

Alzheimer's Disease - Pipeline by Anavex Life Sciences Corp, H1 2018

Alzheimer's Disease - Pipeline by Annexon Inc, H1 2018

Alzheimer's Disease - Pipeline by Aphios Corp, H1 2018

Alzheimer's Disease - Pipeline by Apodemus AB, H1 2018

Alzheimer's Disease - Pipeline by Applied Research using OMIC Sciences SL, H1 2018

Alzheimer's Disease - Pipeline by Aptevo Therapeutics Inc, H1 2018

Alzheimer's Disease - Pipeline by Araclon Biotech SL, H1 2018

Alzheimer's Disease - Pipeline by Archer Pharmaceuticals Inc, H1 2018

Alzheimer's Disease - Pipeline by ArmaGen Inc, H1 2018

Alzheimer's Disease - Pipeline by Asceneuron SA, H1 2018

Alzheimer's Disease - Pipeline by Astellas Pharma Inc, H1 2018

Alzheimer's Disease - Pipeline by AstraZeneca Plc, H1 2018

Alzheimer's Disease - Pipeline by Aucta Pharmaceuticals LLC, H1 2018

Alzheimer's Disease - Pipeline by Avineuro Pharmaceuticals Inc, H1 2018

Alzheimer's Disease - Pipeline by Axon Neuroscience SE, H1 2018

Alzheimer's Disease - Pipeline by Axovant Sciences Ltd, H1 2018

Alzheimer's Disease - Pipeline by Axsome Therapeutics Inc, H1 2018

Alzheimer's Disease - Pipeline by Axxam SpA, H1 2018

Alzheimer's Disease - Pipeline by AZTherapies Inc, H1 2018

Alzheimer's Disease - Pipeline by Beactica AB, H1 2018

Alzheimer's Disease - Pipeline by Berg LLC, H1 2018

Alzheimer's Disease - Pipeline by BioArctic AB, H1 2018

Alzheimer's Disease - Pipeline by Biogen Inc, H1 2018

Alzheimer's Disease - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018

Alzheimer's Disease - Pipeline by BioHealthonomics Inc, H1 2018

Alzheimer's Disease - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2018

Alzheimer's Disease - Pipeline by Bristol-Myers Squibb Co, H1 2018

Alzheimer's Disease - Pipeline by Bsim2, H1 2018

Alzheimer's Disease - Pipeline by Cantabio Pharmaceuticals Inc, H1 2018

Alzheimer's Disease - Pipeline by Cardax Inc, H1 2018

Alzheimer's Disease - Pipeline by Carna Biosciences Inc, H1 2018

Alzheimer's Disease - Pipeline by Celon Pharma SA, H1 2018

Alzheimer's Disease - Pipeline by CHA Bio & Diostech Co Ltd, H1 2018

Alzheimer's Disease - Pipeline by Clera Inc, H1 2018

Alzheimer's Disease - Pipeline by Cognition Therapeutics Inc, H1 2018

Alzheimer's Disease - Pipeline by Cognosci Inc, H1 2018

Alzheimer's Disease - Pipeline by CohBar Inc, H1 2018

Alzheimer's Disease - Pipeline by Connexios Life Sciences Pvt Ltd, H1 2018

Alzheimer's Disease - Pipeline by ConSynance Therapeutics Inc, H1 2018

Alzheimer's Disease - Pipeline by Corium International Inc, H1 2018

Alzheimer's Disease - Pipeline by Coronis NeuroSciences Ltd, H1 2018

Alzheimer's Disease - Pipeline by Cortice Biosciences Inc, H1 2018

Alzheimer's Disease - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Alzheimer's Disease - Pipeline by Crossbeta Biosciences BV, H1 2018

Alzheimer's Disease - Pipeline by Cypralis Ltd, H1 2018

List of Figures

Number of Products under Development for Alzheimer's Disease, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Top 10 Routes of Administration, H1 2018

Number of Products by Stage and Top 10 Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AB Science SA
  • AbbVie Inc
  • AC Immune SA
  • Acadia Pharmaceuticals Inc
  • Accera Inc
  • Actinogen Medical Ltd
  • Acumen Pharmaceuticals Inc
  • Addex Therapeutics Ltd
  • Aequus Pharmaceuticals Inc
  • AFFiRiS AG
  • Alector LLC
  • Allergan Plc
  • Allgen
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll